Cargando…
Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer
Treatment options for colorectal cancer (CRC), especially in advanced stages are still insufficient. There, the discovery of Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) was a bright spot. However, most cancers show resistance toward apoptotic signals. Cyclin-dependent kinas...
Autores principales: | Shen, Xiao, Kretz, Anna-Laura, Schneider, Sandra, Knippschild, Uwe, Henne-Bruns, Doris, Kornmann, Marko, Lemke, Johannes, Traub, Benno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045754/ https://www.ncbi.nlm.nih.gov/pubmed/36979907 http://dx.doi.org/10.3390/biomedicines11030928 |
Ejemplares similares
-
Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
por: Fadeev, Roman, et al.
Publicado: (2019) -
Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo
por: Traub, Benno, et al.
Publicado: (2017) -
Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy
por: Kretz, Anna-Laura, et al.
Publicado: (2018) -
c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1
por: Tian, Xiaodong, et al.
Publicado: (2021) -
Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib
por: Ke, Changhong, et al.
Publicado: (2020)